

Form PTO-1595 (Rev. 03-09)  
OMB No. 0651-0027 (exp. 03/31/2009)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

<b>RECORDATION FORM COVER SHEET</b> <b>PATENTS ONLY</b> <span style="float: right; border: 1px solid black; border-radius: 50%; padding: 2px 5px;">4</span>	
To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.	
<b>1. Name of conveying party(ies)</b> Alaven Pharmaceutical LLC  Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>2. Name and address of receiving party(ies)</b> Name: <u>General Electric Capital Corporation, as agent</u> Internal Address: _____  Street Address: <u>500 W. Monroe</u>  City: <u>Chicago</u> State: <u>IL</u> Country: <u>USA</u> Zip: <u>60661</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>3. Nature of conveyance/Execution Date(s):</b> Execution Date(s) <u>September 16, 2009</u> <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input checked="" type="checkbox"/> Other <u>Third Amended and Restated Patent Security Agreement</u>	<b>4. Application or patent number(s):</b> <input type="checkbox"/> This document is being filed together with a new application. A. Patent Application No.(s) _____ B. Patent No.(s) _____  Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>5. Name and address to whom correspondence concerning document should be mailed:</b> Name: <u>Laura L. Konrath</u> Internal Address: <u>Winston &amp; Strawn LLP</u>  Street Address: <u>35 W. Wacker Drive</u>  City: <u>Chicago</u> State: <u>IL</u> Zip: <u>60601</u> Phone Number: <u>312-558-6352</u> Fax Number: <u>312-558-5700</u> Email Address: <u>lkonrath@winston.com</u>	<b>6. Total number of applications and patents involved:</b> <u>5</u> <b>7. Total fee (37 CFR 1.21(h) &amp; 3.41)</b> \$ <u>200.00</u> <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title)
<b>8. Payment Information</b>  Deposit Account Number <u>232428</u> Authorized User Name <u>Laura Konrath</u>	
<b>9. Signature:</b> <u>Laura L. Konrath</u> <span style="float: right;">10/15/09</span> <div style="display: flex; justify-content: space-between;"> <span>Signature</span> <span>Date</span> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <span>Name of Person Signing</span> <div style="border: 1px solid black; padding: 2px;">             Total number of pages including cover sheet, attachments, and documents:           </div> </div>	

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

American LegalNet, Inc.  
www.FormsWorkflow.com

CH \$200.00 232428 11749732

700420630

**PATENT**  
**REEL: 023379 FRAME: 0789**

Continuation Item 4

**SCHEDULE I  
TO  
PATENT SECURITY AGREEMENT**

**PATENT APPLICATIONS, PATENTS AND PATENT LICENSES**

**PATENTS AND PATENT APPLICATIONS:**

①	Composition and Method for Treating Iron Deficiency Anemia	Patent No. 7,585,527	Issued
②	Reduced Irritant Enema for Treatment of Inflammatory Bowel Disease (IBD)	Application Serial No. 11/749,732	Patent pending
③	Composition and Method for Treating Iron Deficiency Anemia (PCT)	Application Serial No. PCT/US 06/36525	Entered National Phase in Canada
④	Composition and Method for Treating Iron Deficiency Anemia (Continuation of Patent No. 7,585,527)	Application Serial No. 12/506,139	Patent pending
	Composition and Method for Treating Iron Deficiency Anemia	Canadian Application Serial No. 2663584	Patent pending
⑤	Composition and Method for Treating Inflammation of the Large Intestine	Application Serial No. PCT/US 0801253	Entered National Phase in Australia, Canada, Europe and New Zealand
	Composition and Method for Treating Inflammation of the Large Intestine	Australian Application Serial No. 2008211124	Patent pending
	Composition and Method for Treating Inflammation of the Large Intestine	Canadian Application Serial No. not yet assigned	Patent pending
	Composition and Method for Treating Inflammation of the Large Intestine	European Application Serial No. 08713353.4	Patent pending
	Composition and Method for Treating Inflammation of the Large Intestine	New Zealand Application Serial No. 578674	Patent pending

⑤

4

**EXECUTION COPY**

**THIRD AMENDED AND RESTATED PATENT SECURITY AGREEMENT**

This THIRD AMENDED AND RESTATED PATENT SECURITY AGREEMENT, dated as of September 16, 2009 (this "Patent Security Agreement"), by ALAVEN PHARMACEUTICAL LLC, a Delaware limited liability company ("Grantor"), in favor of GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation, in its capacity as Agent for Lenders amends and restates that certain Second Amended and Restated Patent Security Agreement, dated as of December 3, 2008 (the "Existing Patent Security Agreement"), which continues in effect as so amended and restated as set forth herein.

**WITNESSETH:**

WHEREAS, pursuant to that certain Third Amended and Restated Credit Agreement, dated as of the date hereof, by and among Grantor, Alaven Consumer Healthcare, Inc., the Persons named therein as Credit Parties, Agent and the Persons signatory thereto from time to time as Lenders (including all annexes, exhibits or schedules thereto, and as from time to time amended, restated, supplemented or otherwise modified, the "Credit Agreement"), Lenders have agreed to make the Loans and to incur Letter of Credit Obligations for the benefit of Grantor;

WHEREAS, Agent and Lenders are willing to make the Loans and to incur Letter of Credit Obligations as provided for in the Credit Agreement, but only upon the condition, among others, that Grantor shall have executed and delivered to Agent, for itself and the ratable benefit of Lenders, that certain Third Amended and Restated Security Agreement, dated as of the date hereof (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement"); and

WHEREAS, pursuant to the Security Agreement, Grantor is required to execute and deliver to Agent, for itself and the ratable benefit of Lenders, this Patent Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

1 DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in Annex A thereto to the Credit Agreement.

2 GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Grantor hereby grants to Agent, on behalf of itself and Lenders, a continuing first priority security interest in all of Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral"):

(a) all of its Patents and Patent Licenses to which it is a party including those referred to on Schedule I hereto;

(b) all reissues, continuations or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including, without limitation, any claim by Grantor against third parties for past, present or future infringement or dilution of any Patent or any Patent licensed under any Patent License.

3 SECURITY AGREEMENT. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Agent, on behalf of itself and Lenders, pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

4 AMENDMENT AND RESTATEMENT; REAFFIRMATION OF CONTINUING SECURITY. This Patent Security Agreement amends and restates in its entirety the Existing Patent Security Agreement, by and among the Grantor and the Agent, which Existing Patent Security Agreement continues in full force and effect as so amended and restated as set forth herein. Without limiting the generality of the immediately preceding sentence, the Liens granted under the Existing Patent Security Agreement, as so amended and restated as set forth in this Patent Security Agreement, shall in all respects be and remain continuing, securing the payment of all of the Obligations. This Patent Security Agreement represents a continuance of the Existing Patent Security Agreement as amended and restated hereby and not a novation of the Existing Patent Security Agreement. The Grantor acknowledges the execution and delivery of the Credit Agreement on the date hereof and hereby reaffirms the security interests and Liens granted to the Agent for its benefit and the ratable benefit of the Lenders pursuant to the Existing Patent Security Agreement as so amended and restated herein.

[Signature Page Follows]

IN WITNESS WHEREOF, Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**ALAVEN PHARMACEUTICAL LLC,**  
as Grantor,

By: \_\_\_\_\_

Name: Bala Venkataraman


Title: Chief Executive Officer, President

[Signature Page to Alaven Patent Security Agreement]

ACKNOWLEDGMENT OF GRANTOR

STATE OF GEORGIA  
 ) ss.  
COUNTY OF WINNETT

On this 16th day of September 2009 before me personally appeared Bala Venkataraman, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of Alaven Pharmaceutical LLC, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.


  
{seal} Notary Public



[Alaven Patent Security Agreement Acknowledgment of Grantor]

ACCEPTED AND ACKNOWLEDGED BY:

**GENERAL ELECTRIC CAPITAL  
CORPORATION,**  
as Agent

By:   
Name: BRENT SHEPHERD  
Title: Duly Authorized Signatory

[Signature Page to Alaven Patent Security Agreement]

**PATENT**  
**REEL: 023379 FRAME: 0795**

**SCHEDULE I  
TO  
PATENT SECURITY AGREEMENT**

**PATENT APPLICATIONS, PATENTS AND PATENT LICENSES**

**PATENTS AND PATENT APPLICATIONS:**

Composition and Method for Treating Iron Deficiency Anemia	Patent No. 7,585,527	Issued
Reduced Irritant Enema for Treatment of Inflammatory Bowel Disease (IBD)	Application Serial No. 11/749,732	Patent pending
Composition and Method for Treating Iron Deficiency Anemia (PCT)	Application Serial No. PCT/US 06/36525	Entered National Phase in Canada
Composition and Method for Treating Iron Deficiency Anemia (Continuation of Patent No. 7,585,527)	Application Serial No. 12/506,139	Patent pending
Composition and Method for Treating Iron Deficiency Anemia	Canadian Application Serial No. 2663584	Patent pending
Composition and Method for Treating Inflammation of the Large Intestine	Application Serial No. PCT/US 0801253	Entered National Phase in Australia, Canada, Europe and New Zealand
Composition and Method for Treating Inflammation of the Large Intestine	Australian Application Serial No. 2008211124	Patent pending
Composition and Method for Treating Inflammation of the Large Intestine	Canadian Application Serial No. not yet assigned	Patent pending
Composition and Method for Treating Inflammation of the Large Intestine	European Application Serial No. 08713353.4	Patent pending
Composition and Method for Treating Inflammation of the Large Intestine	New Zealand Application Serial No. 578674	Patent pending

(5)